OptiNose — Q4 2019 Earnings Presentation
19 slides from OptiNose's earnings presentation, Mar 5, 2020
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.2 Building a Leading ENT / Allergy Specialty Company Corporate Presentation March 5, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Key Takeaways and Q4 2019 Highlights
Key Takeaways and Q4 2019 Highlights Commercial Strategy Driving Strong XHANCE Growth Substantial Growth Opportunity Remains for XHANCE Strong Balance Sheet - Pharmakon Provides Access to Additional Cash Full Year 2019 Performance Aligned with Company Guidance Providing Initial Company Guidance for
Slide 4: Full Year 2019 Highlights
Full Year 2019 Highlights ($M ) XHANCE Net Revenue +330% XHANCE Net Revenue Growth $30.4 FY 2019/FY 2018 ~154,000 XHANCE Prescriptions in FY 2019 $198 Full Year 2019 XHANCE $7.1 Net Revenue per TRx $125M 2018 2019 Full Year 2019 Operating Expenses (SG&A plus R&D) 4
Slide 5: XHANCE Launch Update
XHANCE Launch Update optinose_
Slide 6: XHANCE New Prescription Trends
XHANCE New Prescription Trends New prescriptions of XHANCE increased 19% in Q4 2019 compared to Q3 2019 XHANCE NRx (in thousands) +19% 25.0 +14% 21.2 20.0 +22% 17.8 +44% 15.6 15.0 12.7 10.0 8.8 5.0 0.0 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 6 Estimated based on monthly prescription data from public sour
Slide 7: XHANCE Refill Prescriptions Trends
XHANCE Refill Prescriptions Trends Refill Prescriptions of XHANCE increased 31% in Q4 2019 compared to Q3 2019 XHANCE NRx (in thousands) 40.0 +31% 33.0 +37% 30.0 +88% 25.2 20.0 18.4 +85% 9.8 10.0 5.3 - Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 7 Estimated based on monthly prescription data from public sour
Slide 8: XHANCE Prescription Trends
XHANCE Prescription Trends Strong growth in both new prescriptions and refills drove XHANCE quarterly prescription growth of 26% in Q4 2019 XHANCE Prescriptions (in thousands) +26% 60.000 +27% 54.3 50.000 +51% 43.0 40.000 33.9 33.0 +59% 30.000 25.2 22.5 18.4 20.000 14.1 9.8 5.3 21.2 10.000 17.8 12.7
Slide 9: XHANCE Share of INS Prescriptions Within the Target Physician Audience
XHANCE Share of INS Prescriptions Within the Target Physician Audience is Growing and the Remaining Opportunity is Large Market share within the XHANCE target physician audience increased consistently in 2019 and we believe share will continue to increase in 2020 XHANCE Share of INS TRx Within Targe
Slide 10: Number of XHANCE Prescribers by Prescribing Frequency
Number of XHANCE Prescribers by Prescribing Frequency Physicians who had more than 15 XHANCE prescriptions filled by their patients in a quarter, a group that averaged ~40 prescriptions per physician in Q4 2019, increased by more than 500% from Q4 2018 to Q4 2019 (828 versus 136). XHANCE Prescribers
Slide 11: Q4 2019 Financial Update
Q4 2019 Financial Update optinose_
Slide 12: Financial Review – Fourth Quarter 2019
Financial Review – Fourth Quarter 2019 Q4 2019 XHANCE Net Revenue Increased 26% to $11.1 Million ($M ) XHANCE Net Revenue Average Net Revenue per TRx $30.4M $11.1 FY 2019 . Average XHANCE net revenue $8.7 of $204 per TRx in Q4 2019 – Increased from $202 in Q3 2019 $6.7 . Average XHANCE net revenue $
Slide 13: First Quarter and Full Year 2020 Financial Guidance
First Quarter and Full Year 2020 Financial Guidance . XHANCE Net Revenue and Average Net Revenue per TRx . FY 2020 expected to more than double compared to FY 2019 . Q1 2020 expected to decrease compared to Q4 2019 as a result of: ‒ Q1 2020 XHANCE Net Revenue per Prescription that is expected to be
Slide 14: Pipeline Update
Pipeline Update optinose_
Slide 15: XHANCE Chronic Sinusitis Indication (sNDA)
XHANCE Chronic Sinusitis Indication (sNDA) The Chronic Sinusitis clinical research program includes two Phase 3b clinical trials {24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter studies} • Top line results expected in second half 2021 Study -3205 • Estimated enrollm
Slide 16: Closing Remarks
Closing Remarks optinose_
Slide 17: Key Takeaways and Q4 2019 Highlights
Key Takeaways and Q4 2019 Highlights Commercial Strategy Driving Strong XHANCE Growth Substantial Growth Opportunity Remains for XHANCE Strong Balance Sheet - Pharmakon Provides Access to Additional Cash Full Year 2019 Performance Aligned with Company Guidance Providing Initial Company Guidance for
Slide 18: Investor Relations
Investor Relations – NASDAQ: OPTN At 31 December 2019: Analyst Coverage 1 – $147 million in cash – Long-term debt: $80 million BMO: Gary Nachman – 45.9 million common shares o/s – 10.1 million options & warrants o/s Cantor Fitzgerald: Brandon Folkes Cowen: Ken Cacciatore Optinose Investor Contact Je
Slide 19: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation March 5, 2020